GlassScriptPhysician profile
Saurabh Chandan
NPI 1194145169
$6,019.71
in general payments reported to CMS, 2019-2025
26 companies · $603 in 2025
The $603 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $88.75 · 2020: $52.70 · 2021: $360 · 2022: $518 · 2023: $1,423 · 2024: $2,974 · 2025: $603.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,556 · Education: $1,336 · Travel and Lodging: $1,107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,556.48 |
| Education | $1,336.11 |
| Travel and Lodging | $1,107.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Erbe USA INC | $1,320.00 | 2024 | Vio3 Ej2 Hybrid Knife |
| Olympus Corporation of The Americas | $1,269.05 | 2024-2025 | Olympus, Single Use Electrosurgical Knife Kd-655, Disposable Distal Attachment |
| Gilead Sciences, INC. | $494.29 | 2021-2024 | |
| Abbvie INC. | $473.48 | 2020-2025 | Skyrizi, Rinvoq, Viberzi |
| Janssen Biotech, INC. | $363.14 | 2020-2025 | Stelara, Simponi Aria, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $316.94 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $303.34 | 2021-2024 | Xifaxan, Trulance |
| Aimmune Therapeutics, INC. | $218.76 | 2024-2025 | Zenpep |
| Genzyme Corporation | $208.79 | 2022-2025 | |
| Nestle Healthcare Nutrition INC. | $164.92 | 2023 | |
| Cook Medical LLC | $126.99 | 2025 | Hemospray |
| Boston Scientific Corporation | $112.86 | 2019-2025 | General - Therapies |
| Steris Corporation | $101.16 | 2022 | |
| Ironwood Pharmaceuticals, INC | $84.46 | 2022-2023 | Linzess |
| Celgene Corporation | $75.58 | 2021-2023 | Zeposia |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $70.64 | 2023-2024 | Dupixent |
| Intercept Pharmaceuticals, INC. | $66.75 | 2021-2024 | Ocaliva |
| Medtronic, INC. | $62.14 | 2025 | Manoscan |
| Lilly USA, LLC | $39.84 | 2023-2025 | Omvoh |
| Ambu INC. | $28.91 | 2022 | |
| Pfizer INC. | $27.02 | 2021 | |
| Vivus LLC | $24.54 | 2025 | Pancreaze |
| Ferring Pharmaceuticals INC. | $19.42 | 2023 | Rebyota |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.20 | 2023 | Cyltezo |
| Alnylam Pharmaceuticals INC. | $15.37 | 2024 | Givlaari |
| Sandoz INC. | $15.12 | 2023 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saurabh Chandan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.